Why is Piramal Pharma falling/rising?

As of 17-Jul, Piramal Pharma Ltd's stock price is currently at Rs 216.50, reflecting an increase of Rs 1.8 or 0.84%. The stock has shown strong performance recently, with a 7.87% increase over the past week and an 11.00% rise over the past month, significantly outperforming the Sensex, which has declined by 1.12% in the same week and increased by only 0.83% in the past month. Today's price summary indicates that the stock reached an intraday high of Rs 220.9, and it has been trading above its 5-day, 20-day, 50-day, and 100-day moving averages, although it remains below the 200-day moving average. However, there is a noted decrease in investor participation, with delivery volume falling by 30.68% against the 5-day average. The company has reported impressive growth in operating profit and net sales, contributing to its positive market performance, despite a high Debt to EBITDA ratio indicating potential challenges in servicing debt.
In the broader market context, Piramal Pharma's recent performance contrasts sharply with the benchmark, as it has generated a return of 41.69% over the past year, while the BSE500 has only returned 0.26%. This strong performance is supported by high institutional holdings, which suggest confidence from more knowledgeable investors. However, the company faces challenges with its high Debt to EBITDA ratio and low Return on Equity, which may raise concerns about its long-term profitability and valuation. Despite these negatives, the stock's recent upward movement can be attributed to its strong operational results and market-beating performance, indicating a complex interplay of factors influencing investor sentiment.